Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 4

MERRIMAC Form 4 June 19, 2015	K PHARMACEU	JTICALS	INC								
FORM Check this if no longe subject to	4 UNITED S	STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940								PPROVAL 3235-0287 January 31, 2005 average	
Section 16 Form 4 or Form 5 obligation may contin <i>See</i> Instruct 1(b).	Filed purs s Section 17(a									rs per 0.5	
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> Stewart Edward J.		S N H	2. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [MACK]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) (First) (Middle) C/O MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201			3. Date of Earliest Transaction(Month/Day/Year)06/18/2015					XOfficer (give titleOther (specify below) below) Head of Commercial			
	(Street)	Street) 4. If Amendm Filed(Month/D						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
CAMBRIDO	GE, MA 02139							Form filed by M Person			
(City)	(State) (Zip)	Table	e I - Non-De	erivative S	Securi	ties Acc	quired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	Code (D) (Instr. 8) (Instr. 3, 4 and 5)		Securities Energically Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock	06/18/2015			Code V M	Amount 2,000	or (D) A	Price \$ 1.81	(Instr. 3 and 4) 23,385	D		
Common Stock	06/18/2015			S <u>(1)</u>	2,000	D	\$ 12	21,385	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of
information contained in this form are not
required to respond unless the formSEC 1474
(9-02)

Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number or f Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	e Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 1.81	06/18/2015		М	2,000) (2)	09/22/2018	Common Stock	2,000	

Reporting Owners

Relationships Reporting Owner Name / Address 10% Owner Officer Other Director Stewart Edward J. C/O MERRIMACK PHARMACEUTICALS, INC. Head of Commercial ONE KENDALL SQUARE, SUITE B7201 CAMBRIDGE, MA 02139 Signatures /s/ Jeffrey A. Munsie, 06/19/2015 attorney-in-fact **Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- (2) This option is fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.